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Abstract
Purpose: To elucidate the prognostic factors in the spontaneous rupture of hepatocellular carcinoma (HCC) and 
to determine whether transcatheter arterial embolisation (TAE) is associated with better prognosis compared to 
conservative treatment. 
Material and methods: A retrospective multicentre study was conducted involving 71 patients with spontaneous rup-
ture of HCC. A conservative treatment group (Cons T group) included 20 patients, while a transcatheter arterial 
embolisation group (TAE group) included 51 patients. 
Results: The median survival time (MST) in the Cons T group was only 16 days and the survival rate was 39% at 
one month, whereas the MST in the TAE group was 28 days and the one month survival rate was 63%. However, 
there is no statistically significant difference in the overall survival between Cons T and TAE groups (p = 0.213). 
Multivariable analysis identified only the presence of distant metastasis as an independent prognostic factor (p = 0.023). 
A subanalysis including patients without distant metastasis showed that the presence of portal vein tumour throm-
bosis was a significant prognostic factor (p = 0.015).
Conclusions: Distant metastasis appears to be a prognostic factor in spontaneous rupture of HCC. In cases without 
distant metastasis, portal vein tumour thrombosis could influence the prognosis. Our data failed to prove any benefit 
of TAE as the primary management.
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Introduction
The spontaneous rupture of hepatocellular carcinoma 
(HCC) is a rare but life-threatening presentation of this dis-
ease and cause of death in 6.4% of such cases in Japan [1]. 
The affected patients frequently have poor liver function 
due to liver cirrhosis and advanced tumour stage, and pre-
vious reports showed that the one-month mortality rate 
ranged from 28% to 71% with a median survival period 
of 4 to 32 weeks [2-8]. The spontaneous rupture of HCC 
has been treated with several different methods such as 
conservative treatment (Cons T) and transcatheter arterial 
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embolisation (TAE). However, due to its relative rarity and 
difficulty in conducting prospective comparisons, there is 
little consensus on the appropriate management and prog-
nostic factors. Therefore, we introduced a multi-centre ret-
rospective study to elucidate the prognostic factors in the 
spontaneous rupture of HCC and to determine whether 
TAE is associated with better prognosis than Cons T.
Material and methods
Study population and clinical data
This multicentre retrospective study was approved by 
the Institutional Review Board of each participating in-
stitution, and the need for informed consent acquisition 
was waived.
We retrospectively analysed pooled data obtained from 
the clinical and radiological records of 71 consecutive pa-
tients (56 males and 15 females; age range 32-86 years, 
mean 65.1 years) with spontaneous rupture of HCC, who 
were treated between October 1989 and December 2011 
in three different sites in two countries: hospital A (15 pa-
tients), B (43 patients), and C (13 patients). Cause of liver 
damage (hepatitis type), Child-Pugh classification (A, B, 
or C), presence/absence of hepatic encephalopathy, ascites, 
shock vital (systolic blood pressure < 80 mmHg), portal 
vein tumour thrombosis, distant metastasis, and past histo-
ry of HCC treatment, tumour size (maximum diameter on 
axial CT image), tumour morphology (massive or diffuse), 
serum α-fetoprotein (AFP), blood chemistry data (serum 
albumin, total bilirubin, aspartate aminotransferase [AST], 
alanine transaminase [ALT], blood urea nitrogen [BUN], 
and creatinine), haemoglobin, prothrombin time, primary 
management (TAE or conservative), and secondary man-
agement (TAE or surgery or none) were recorded. 
Treatment methods
Attending physician assessed patients’ states and conduct-
ed the treatment method (TAE or Cons T) and obtained 
consent from the patient or patient’s family. TAE was 
approached from femoral artery with the Seldinger tech-
nique. Angiographic catheter was inserted in the hepatic 
artery and contrast agent was injected, so that branches 
of bleeding hepatic artery were identified. As an embolic 
material, gelatin sponge that was cut into small cubes of 
approximately 1-2 mm3 in size was injected into bleeding 
arteries. The embolic procedure was finished because we 
could confirm the stopping of bleeding by angiography. In 
conservative treatment, a haemostatic agent and/or pain 
relief drug was intravenously infused.
Statistical analyses
The χ2 test for independence or the Fisher exact test was 
used for comparison of the two groups. To determine 
factors influencing overall survival, a univariate analysis 
was performed using the Kaplan-Meier method and a log-
rank test. The survival period was defined as the length of 
time from the onset of the spontaneous rupture of HCC 
until death. Subsequently, to identify independent prog-
nostic factors, multivariable analysis was performed using 
the Cox proportional hazard model from which hazard 
ratios with their confidence intervals and p values were 
reported. P < 0.05 was considered statically significant for 
all analyses. All statistical analyses were performed using 
StatView; SAS software.
Results
The patients’ characteristics are shown in Table 1. Cause 
of liver damage was alcoholic in seven patients (10%), 
hepatitis B in 28 patients (39%), hepatitis C in 18 patients 
(25%), and non-B non-C in six patients (8%). Eight patients 
(11%) were in Child-Pugh A class, 34 (48%) in B class, and 
22 (31%) in C class. Five patients (7%) had hepatic enceph-
alopathy. Fifty-nine patients (83%) had ascites. Ten patients 
(16%) had shock vital at the time of admission. Mean tu-
mour size of HCCs was 7.5 cm. Forty-two patients (59%) 
had past history of HCC treatment. Mean follow-up period 
was 106.8 days (range 0-2972 days). 
Conservative treatment (Cons T group) was employed 
as the primary management in 20 patients (28%), while 
transcatheter arterial embolisation (TAE group) was per-
formed in the remaining 51 patients (72%). Hepatic en-
cephalopathy was more frequent in the Cons T group than 
in the TAE group (p = 0.001). In addition, serum total bil-
irubin was significantly higher (p = 0.012) and prothrom-
bin time was significantly shorter (p = 0.003) in the Cons T 
group than in the TAE group. No significant difference 
was found in the other variables between the two groups.
The median survival time (MST) was 22 days, and one-
month mortality rate was 56% in all patients. MST in the 
Cons T group was 16 days and the survival rate was poor: 
75 % at seven days, 60 % at 14 days, 39 % at one month, and 
22% at three months. On the other hand, MST in TAE group 
was 28 days and the survival rate was 83% at seven days, 
73% at 14 days, 63% at one month, 27% at three months, 
18% at 12 months, and 18% at 24 months. However, there 
was no statistically significant difference in the survival rate 
between the Cons T and TAE groups (p = 0.213) (Table 2, 
Figure 1). Factors associated with significantly lower overall 
survival included being female (p = 0.006), higher Child-
Pugh grade (p = 0.012), presence of hepatic encephalopa-
thy (p < 0.001), presence of portal vein tumor thrombosis 
(p < 0.001), presence of distant metastasis (p = 0.005), pres-
ence of past history of HCC (p = 0.049), lower serum al-
bumin (p = 0.018), higher total bilirubin (p < 0.001), and 
longer prothrombin time (p = 0.017) (Table 2). 
A multivariable analysis admitted factors that were 
shown to be significant in the univariate analysis. Hepat-
ic encephalopathy, serum total bilirubin, albumin, and 
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Table 1. Patient characteristics of the analysed cohort and comparisons between conservative treatment group (Cons T) and transcatheter arterial embo-
lisation (TAE) groups
Variables Total Cons T group TAE group p value
Patients, n (%) 71 20 (28) 51 (72)
Age (y) 65.1 (13.3) 68.2 (10.7) 63.8 (14.1) 0.378 NS
Sex, n (%) 0.621 NS
Male 56 (79) 15 (75) 41 (80)
Female 15 (21) 5 (25) 10 (20)
Cause of liver damage, n (%) 0.767 NS
Alcohol 7 (10) 1 (5) 6 (12)
Hepatitis B 28 (39) 7 (35) 21 (41)
Hepatitis C 18 (25) 4 (20) 14 (27)
Non-B, non-C 6 (8) 1 (5) 5 (10)
Child-Pugh classification, n (%) 0.786 NS
A 8 (11) 2 (10) 6 (12)
B 34 (48) 8 (40) 26 (51)
C 22 (31) 7 (35) 15 (29)
Hepatic encephalopathy, n (%) 0.002
Present 5 (7) 4 (20) 1 (2)
Ascites, n (%) 0.209 NS
Present 59 (83) 15 (75) 44 (86)
Shock vital, n (%) 0.719 NS
 Present 16 (22) 4 (20) 12 (23)
Tumour size (cm) 7.5 (3.9) 7.2 (0.8) 7.6 (4.1) 0.842 NS
Tumour morphology, n (%) 0.778 NS
Massive 34 (47) 6 (30) 28 (54)
 Diffuse 14 (19) 5 (25) 9 (17)
Portal vein tumour thrombosis, n (%) 0.326 NS
 Present 19 (27) 7 (35) 12 (24)
History of HCC treatment, n (%) 0.089 NS
Present 42 (59) 15 (75) 27 (53)
Secondary management, n (%) 0.083 NS
 TAE 6 (8) 0 (0) 6 (12)
 Surgery 1 (1) 1 (5) 0 (0)
 None 62 (87) 19 (95) 43 (84)
Serum albumin (g/l) 2.85 (0.64) 2.81 (0.55) 2.87 (0.68) 0.720 NS
Serum total bilirubin (µmol/l) 3.47 (5.08) 5.89 (8.62) 2.51 (2.39) 0.012
Serum AFP (ng/ml) 47821 (113213) 7721 (14084) 58132 (125013) 0.238 NS
AST (U/l) 197.8 (262.5) 205.0 (218.9) 195.0 (278.9) 0.889 NS
ALT (U/l) 114.7 (240.7) 96.6 (118.5) 121.4 (273.4) 0.705 NS
Haemoglobin (g/dl) 8.99 (2.49) 9.16 (2.53) 8.92 (2.50) 0.726 NS
Prothrombin time (s) 32.8 (24.6) 18.7 (15.1) 37.8 (25.0) 0.003
BUN (mg/dl) 24.2 (15.7) 26.8 (20.4) 23.3 (13.7) 0.411 NS
CRE (mg/dl) 1.43 (1.47) 1.23 (0.79) 1.50 (1.65) 0.524 NS
Cons T – conservative treatment, TAE – transcatheter arterial embolization, NS – not significant, AFP – α-fetoprotein, AST – aspartate aminotransferase, ALT – alanine aminotransferase 
Continuous variables are indicated in the mean (SD)
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Table 2. Univariate analysis searching for factors influencing overall survival
Variables Number Median survival (day) p value (log-rank)
Age 0.316 NS
≤ 58 24 17
> 58 and < 73 22 25
≥ 73 25 20
Sex 0.006
Male 56 25
Female 15 10
Institution 0.855 NS
A  15 20
B 43 17
C 13 28
Primary management 0.213 NS
TAE 51 28
Cons T 20 16
Child-Pugh classification 0.012
A  8 30
B 34 22
C 22 11
Hepatic encephalopathy < 0.001
Absent 64 25
Present 5 1
Ascites 0.988 NS
Absent 11 17
Present 59 22
Shock vital 0.105 NS
Absent 54 28
Present 16 10
Tumour size (cm) 0.832 NS
≤ 4.3 17 29
> 4.3 and < 7.8 18 25
≥ 7.8 19 11
Tumour morphology 0.748 NS
Massive 34 22
Diffuse 14 16
Portal vein tumour thrombosis < 0.001
Absent 52 29
Present 19 10
Distant metastasis 0.005
Absent 55 25
Present 16 14
History of HCC treatment 0.049
Absent 29 18
Present 42 28
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Variables Number Median survival (day) p value (log-rank)
Serum albumin (g/l) 0.018
≤ 2.5 23 11
> 2.5 and < 3.2 21 38
≥ 3.2 20 20
Serum total bilirubin (µmol/l) < 0.001
≤ 1.2 23 34
> 1.2 and < 2.5 23 20
≥ 2.5 24 10
Serum AFP (ng/ml) 0.173 NS
≤ 420 14 30
> 420 and < 15 700 15 15
≥ 15 700 15 18
AST (U/l) 0.079 NS
≤ 63 23 28
> 63 and < 144 23 18
≥ 144 24 13
ALT (U/l) 0.228 NS
≤ 32 24 30
> 32 and < 62 24 17
≥ 62 22 14
Haemoglobin (g/dl) 0.125 NS
≤ 7.7 23 16
> 7.7 and < 10.0 22 22
≥ 10.0 25 30
Prothrombin time (s) 0.017
≤ 14 23 34
> 14 and < 40 23 10
≥ 40 23 22
BUN (mg/dl) 0.732 NS
≤ 16.1 24 25
> 16.1 and < 23.3 24 20
≥ 23.3 22 25
CRE (mg/dl) 0.974 NS
≤ 0.8 24 25
> 0.8 and < 1.3 21 17
≥ 1.3 25 18
CI – confidence interval, TAE – transcatheter arterial embolization, Cons T – conservative treatment, NS – not significant, HCC – hepatocellular carcinoma, CI – confident interval, AFP – α-fetoprotein, 
AST – aspartate aminotransferase, ALT – alanine aminotransferase
Table 2. Cont.
prothrombin time were excluded from the analysis be-
cause they are included in the Child-Pugh classification. 
The multivariable analysis identified only the presence of 
distant metastasis as an independent factor determining 
lower overall survival (p = 0.023) (Table 3, Figure 2). 
We performed an additional subanalysis including 
55 patients without distant metastasis. A multivariable 
analysis showed that the presence of portal vein tumour 
thrombosis was the only significant independent prognos-
tic factor (p = 0.015) (Table 4, Figure 3).
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Discussion
In the past, patients with spontaneously ruptured HCC 
were treated by various surgical procedures including peri-
hepatic packing, suture plication of bleeding tumour, injec-
tion of absolute alcohol, hepatic artery ligation, and liver 
resection [2-13]. However, because those patients tend to 
have advanced disease and poor liver function from cir-
rhosis, invasive surgical interventions may not be tolerated. 
Thus, less invasive treatments such as TAE or conservative 
management are chosen in the majority of cases. TAE is 
considered to be highly effective in controlling haemor-
rhage due to ruptured HCC, and we expected that it would 
improve prognosis of the affected patients compared to 
conservative treatment. In fact, our results showed a bet-
ter prognosis in the TAE group (MST = 28 days) than in 
the Cons T group (MST = 16 days), but no significant dif-
ference in overall survival was revealed between the two 
groups (p = 0.213). An earlier retrospective study reported 
by Kirikoshi et al. showed a significantly better prognosis 
in patients treated with TAE (MST = 224.8 days) than in 
those treated with conservative therapy (MST = 13.1 days) 
Table 4. Multivariable analysis including patients without distant metas-
tasis
Variables Hazard 
ratio
95% CI p value
Sex (female) 2.249 0.894-5.657 0.085 NS
Child-Pugh classification 
C 1.849 0.368-9.283 0.455 NS
B 1.379 0.303-6.260 0.678 NS
Portal vein tumour thrombosis 
(present)
2.896 1.222-6.864 0.015
History of HCC treatment 
(present)
1.482 0.616-3.564 0.380 NS
CI – confidence interval, NS – not significant, HCC – hepatocellular carcinoma
Figure 2. Cumulative survival rates in the absence of distant metastasis 
group (n = 55) and in the presence group (n = 16). Overall survival rate 
is significantly higher in the absence group than in the presence group 
(p = 0.005)
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Figure 3. Cumulative survival rates in the absence of portal vein tumor 
thrombosis group (n = 42) and in the presence group (n = 13) without 
distant metastasis. Overall survival rate is significantly higher in the absence 
group than in the presence group (p < 0.001)
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Table 3. Multivariable analysis searching for factors influencing overall 
survival
Variables Hazard 
ratio
95% CI p value
Sex (female) 1.967 0.889-4.355 0.095 NS
Child-Pugh classification
C 2.208 0.574-8.491 0.249 NS
B 1.282 0.361-4.548 0.700 NS
Portal vein tumor thrombosis 
(present)
2.080 0.962-4.497 0.063 NS
Distant metastasis (present) 2.313 1.123-4.767 0.023
History of HCC treatment 
(present)
1.524 0.731-3.174 0.261 NS
CI – confidence interval, NS – not significant, HCC – hepatocellular carcinoma
Figure 1. Cumulative survival rates in the conservative treatment (Cons T) 
group (n = 20) and in the transcatheter arterial embolization (TAE) group 
(n = 51). Difference between groups is not significant (p = 0.213)
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[11]. The discrepant results can possibly be accounted for 
by relatively better liver function in their patients than 
those in our study: percentage of child A patients was 24% 
and the mean of total bilirubin was 1.8 mmol/l in their 
study, while percentage of child A patients was 11% and 
the mean total bilirubin was 3.4 mmol/l in our study. 
Despite a multitude of previous studies, no gener-
al consensus has been achieved on prognostic factors in 
patients with spontaneous rupture of HCC. In our multi-
variable analysis, the presence of distant metastasis was 
the only significant factor that was associated with lower 
overall survival (Table 3, Figure 2). Sixteen patients had 
distant metastasis (lung in 11 cases, lymph node in two 
cases, peritoneum in one case, adrenal gland in one case, 
and bone in one case), and their MST was 10 days (22 days 
in the absence group). Aoki et al. [6] analysed patients with 
spontaneous rupture of HCC and reported that stage IV 
group was associated with worse prognosis than the 
stage I-III group. Ueno et al. [14] reported that extrahe-
patic metastasis showed prognostic significance in multi-
variate analysis of unresectable HCC patients treated with 
transcatheter arterial chemoembolisation therapy. Distant 
metastasis of HCC has been regarded as a terminal event, 
and intrahepatic lesions were not actively treated in such 
cases [15]. However, some pervious reports showed that 
the metastatic lesion of HCC was a minor cause of death 
and the main cause of death was advanced intrahepatic 
lesions. In those reports, it was said that if a patient’s liver 
status is good, treatment for liver and metastatic lesion 
may improve survival [16-19]. In general, ruptured HCC 
patient’s liver status was mostly not good. In cases where 
distant metastasis is present, one should be careful about 
introducing TAE for treatment of ruptured HCC. Con-
servative treatment may be preferred in such cases.
Our univariate analysis revealed several additional 
items as possible prognostic factors. The presence of portal 
vein tumour thrombosis was significantly associated with 
lower overall survival (Table 2). MST of 19 patients with 
portal vein tumour thrombosis was 10 days while that of 
the absence group was 29 days. Okazaki et al. performed 
TAE in 38 patients with ruptured HCC. Although patients 
without portal vein tumour thrombus showed longer MST 
(133 days) than those with it (90 days), no significant dif-
ference in prognosis was demonstrated [13]. Nevertheless, 
our subanalysis including patients without distant metas-
tasis (n = 55) identified it as an independent prognostic 
factor (p = 0.015) (Table 4, Figure 3). Thus, we consider 
that portal vein tumour thrombus could be a prognostic 
factor of ruptured HCC. Portal vein tumour thrombus 
was found in 12-39% of patients with HCC [1,20-22] and 
18-57% of patient with ruptured HCC [6,12,13]. Yama-
da et al. [23] reported that TAE was contraindicated for 
patients with portal vein tumour thrombus, because TAE 
might increase the risk of ischaemic liver damage. On the 
other hand, some groups reported that TAE was a safe 
treatment method of HCC with peripheral portal vein 
tumour thrombus if the patient has good liver function 
[24-27]. In our study, 19 patients (26%) had portal vein 
tumour thrombus, and TAE was conducted in 12 cases. 
There was no significant difference in the survival rate be-
tween TAE and conservative treatment (p = 0.1329). When 
central portal vein tumour thrombus is present, patients 
with ruptured HCC should be treated conserva tively.
Tarantino et al. [5] reported that Child-Pugh A vs. B/C 
variables were statistically significant for overall survival 
of ruptured HCC patients. In agreement with their report, 
there was a significant difference in overall survival by 
Child-Pugh classification factor (C > A) in our univariate 
analysis (Table 2), although significant association was 
not confirmed in the multivariable analysis. This could be 
partly due to the small number of patients in the Child-
Pugh A group (n = 8). 
The presence of hepatic encephalopathy, which is one 
of the criteria of Child-Pugh classification, was associat-
ed with lower overall survival in our univariate ana lysis 
(Table 2). Five patients had hepatic encephalopathy, and 
their MST was one day, whereas MST of 64 patients without 
it was 25 days. Kim et al. [7] studied 62 patients with rup-
tured HCC and found that early deaths were independently 
associated with the presence of hepatic ence phalopathy.
Serum levels of albumin and total bilirubin are also 
included in the criteria of Child-Pugh classification. In 
the univariate analysis, lower albumin and higher biliru-
bin levels were found to be significantly associated with 
worse prognosis in ruptured HCC (Table 2). Okazaki et al. 
[13] reported that MST of the lower serum bilirubin value 
group (≤ 3.0 mg/dl) was 165 days and that of the higher 
value group (> 3.0 mg/dl) was 13 days, and that there was 
significant difference in the survival rate between lower and 
higher value groups. In our study, MST of the lower serum 
bilirubin value group (≤ 3.0 µmol/l) was 25 days and that of 
the higher serum bilirubin value group (> 3.0 µmol/l) was 
14 days. 
There were some limitations in our study. Selection 
bias may exist due to the retrospective nature of this study. 
The Cons T group was relatively small. 
Conclusions
The presence/absence of distant metastasis appears to 
be a prognostic factor in spontaneous rupture of HCC. In 
cases of absent metastasis, portal vein tumour thrombosis 
could influence the prognosis. Although TAE was associ-
ated with longer survival than conservative treatment, our 
data failed to provide evidence of a significant impact of 
TAE as the primary management of ruptured HCC. TAE 
should be conducted with caution, especially in patients 
with advanced disease. 
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